Homocysteine and Diabetic Retinopathy
- Laima Brazionis, BSC, MHN, PHD1,
- Kevin Rowley, Sr., PHD2,
- Catherine Itsiopoulos, BSC, MPH, PHD1,
- Colin Alexander Harper, MBBS, FRACS3 and
- Kerin O’Dea, BSC, PHD1
- 1Department of Medicine, University of Melbourne, St. Vincent's Hospital, Victoria, Australia
- 2Onemda VicHealth Koori Health Unit, Centre for Health and Society, School of Population Health, University of Melbourne, Victoria, Australia
- 3Centre for Eye Research Australia, East Melbourne, Victoria, Australia
- Address correspondence and reprint requests to Laima Brazionis, Department of Medicine, University of Melbourne, St. Vincent's Hospital, P.O. Box 2900, Fitzroy, Victoria 3065, Australia. E-mail: laimab{at}medstv.unimelb.edu.au
Abstract
OBJECTIVE—Homocysteine is an emerging risk factor for cardiovascular and nondiabetic ocular vaso-occlusive diseases. However, studies of the relationship between homocysteine and diabetic retinopathy have reported inconsistent results. The purpose of this study was to evaluate the relationship between plasma total homocysteine concentration and diabetic retinopathy.
RESEARCH DESIGN AND METHODS—We assessed the homocysteine-retinopathy relationship in 168 men and women with type 2 diabetes in a community-based, cross-sectional study. We photodocumented diabetic retinopathy status and measured plasma total homocysteine concentration using a commercial fluorescence polarization immunoassay enzymatic kit. Data for selected clinical/demographic variables and established risk factors for diabetic retinopathy were obtained from fasting blood samples and an interviewer-assisted lifestyle questionnaire.
RESULTS—A higher mean plasma total homocysteine concentration was observed in diabetic individuals with retinopathy than in those without retinopathy (11.5 μmol/l [95% CI 10.4–12.5] vs. 9.6 μmol/l [9.1–10.2], P = 0.001). Furthermore, the relationship between homocysteine and diabetic retinopathy was not explained by renal dysfunction and was independent of the other major risk factors for diabetic retinopathy (duration of diabetes, A1C, and systolic blood pressure) and determinants of higher homocysteine concentrations (age, sex, and red cell folate) (odds ratio 1.20 [95% CI 1.023–1.41], P = 0.024).
CONCLUSIONS—Plasma total homocysteine concentration may be a useful biomarker and/or a novel risk factor for increased risk of diabetic retinopathy in people with type 2 diabetes.
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 26 September 2007. DOI: 10.2337/dc07-0632.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Accepted September 17, 2007.
- Received April 1, 2007.
- DIABETES CARE
